Disopyramide Phosphate Capsule, Extended Release
Category: Cardiovascular
FDA status: To Be Discontinued · Last FDA update: Aug 24, 2026 · First posted: Aug 24, 2026 · 1 manufacturers, 2 listed presentations
As of Aug 24, 2026, the FDA lists Disopyramide Phosphate Capsule, Extended Release as being discontinued. Of 2 manufacturer presentations, 2 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Norpace CR, Capsule, Extended Release, 100 mg (NDC 0025-2732-31) NDC 0025-2732-31 |
Pfizer Inc. | Not specified | Discontinuation of the manufacture of the drug |
| Norpace CR, Capsule, Extended Release, 150 mg (NDC 0025-2742-31) NDC 0025-2742-31 |
Pfizer Inc. | Not specified | Discontinuation of the manufacture of the drug |
Related medications in shortage
Other Cardiovascular medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Disopyramide Phosphate Capsule, Extended Release (FDA data as of Aug 24, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Disopyramide Phosphate Capsule, Extended Release. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/disopyramide-phosphate-capsule-extended-release.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).